The UAMS Myeloma Institute is an international leader in the treatment and study of multiple myeloma and related diseases. Our team of renowned scientists and clinicians translates advances from the laboratory into novel clinical treatments, continually expanding the boundaries of myeloma research and therapy toward cure.
The Myeloma Institute has more than 25 years of clinical and research excellence focused exclusively on multiple myeloma and related conditions, and is known worldwide for its high volume of patients and outstanding outcomes.
Total Therapy 6: Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Principal Investigator: Dr. Gareth Morgan